Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia
In this real-world study, early discontinuation was more common in patients initiating a BTKi in contrast to VEN-O. Patients who initiated a BTKi also had high rates of subsequent treatment and hospitalization.
Authors
- Steven E. Marx (ORCID: https://orcid.org/0000-0002-2171-1923)
- Justin Puckett (ORCID: https://orcid.org/0000-0002-5135-7216)
- Dureshahwar Jawaid
- Nnadozie Emechebe
- Scott F. Huntington (ORCID: https://orcid.org/0000-0001-7071-6475)
- Joanna Meehan Rhodes (ORCID: https://orcid.org/0000-0002-5068-9040)
- Beenish S. Manzoor (ORCID: https://orcid.org/0000-0002-0329-3465)
- Sachin Kamal‐Bahl
- Arliene Ravelo (ORCID: https://orcid.org/0000-0001-7554-3008)
- Jalpa A. Doshi (ORCID: https://orcid.org/0000-0002-3263-4337)
Institutions
- Rutgers, The State University of New Jersey (US)
- AbbVie (United States) (US)
- Yale University (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1200/op.24.00220
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00